

Based on their meta-analytic review, Zhou and colleagues<sup>1</sup> conclude that “fluoxetine (alone or in combination with CBT) seems to be the best choice for the acute treatment of moderate-to-severe depressive disorder in children and adolescents” (p. 581). The meta-analysis, however, suffers from several statistical and methodological flaws that belie this and other conclusions.

First, *the authors’ own data* indicate that the conclusions about the superiority of fluoxetine (FLU) are unjustifiable. Almost none of the comparisons between FLU/FLU+CBT and other treatments are significant (Figure 3). Furthermore, Figure 4 demonstrates that the confidence intervals of most interventions vs. pill placebo overlap with that of FLU and FLU+CBT, indicating that none should be considered superior to any other.

Second, the meta-analysis gives false impressions of the precision of individual effects. Take, for example, the conclusion regarding the relative inefficacy of psychodynamic therapy (PDT) compared to fluoxetine (FLU) plus CBT ( $d = 1.14$ ). The total number of trials that examined PDT was two.<sup>2,3</sup> In one of these studies,<sup>3</sup> 74% of patients treated with PDT achieved remission post-therapy and 100% in the 6-month follow-up; in the other,<sup>2</sup> short-term PDT demonstrated comparable outcomes to both CBT and a manualized Brief Psychosocial Intervention (BPI), which was incorrectly categorized by the authors as a “psychological placebo.” These data are hardly compatible with the conclusion of PDT being inferior to FLU + CBT or that PDT is non-significantly inferior to *pill placebo* (p. 596).

Part of the problem with the network meta-analysis presented by Zhou et al.<sup>1</sup> involves the assumption of transitivity, i.e., that studies share similar characteristics relevant to estimating an effect size, permitting the comparison of treatments that have never been directly contrasted.<sup>4</sup> Most psychological treatments in the meta-analysis have never been compared to pill placebo or FLU, meaning that establishing transitivity is vital. In the example of PDT, the authors suggest that psychodynamic therapy is non-significantly inferior to pill placebo ( $d = -0.41$ ), even though in the two included trials, PDT performed *very* comparably to family therapy ( $d = -0.03$  vs. placebo) and CBT ( $d = 0.05$ ); the *direct* findings from the individual trials, then, appear to contradict the results drawn from the *indirect* evidence of the network analyses. While the authors argue that inconsistency was within tolerated bounds, consistency tests are very underpowered under conditions like the present analysis;<sup>5</sup> the assessed inconsistency is likely an *underestimate*. Consistency is also impossible to estimate if there are *no* direct comparisons.

The authors’ conclusions could have the unfortunate consequence of patients failing to receive other treatments that have demonstrated efficacy, and not just fluoxetine. Access to effective evidence-based mental health care is challenging enough, and recommending that clinicians provide one treatment over others—when those other treatments are *just as useful*—only exacerbates the situation.

## References

1. Zhou X, Teng T, Zhang Y, et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. *The Lancet Psychiatry* 2020; **7**(7): 581-601.

2. Goodyer IM, Reynolds S, Barrett B, et al. Cognitive behavioural therapy and short-term psychoanalytical psychotherapy versus a brief psychosocial intervention in adolescents with unipolar major depressive disorder (IMPACT): a multicentre, pragmatic, observer-blind, randomised controlled superior. *The Lancet Psychiatry* 2016; **0366**: 1-11.
3. Trowell J, Joffe I, Campbell J, et al. Childhood depression: a place for psychotherapy. An outcome study comparing individual psychodynamic psychotherapy and family therapy. *Eur Child Adolesc Psychiatry* 2007; **16**: 157-67.
4. Keefe JR. Heightened risk of false positives in a network meta-analysis of social anxiety. *The Lancet Psychiatry* 2015; **2**(4): 292-3.
5. Veroniki AA, Mavridis D, Higgins JPT, Salanti G. Characteristics of a loop of evidence that affect detection and estimation of inconsistency: a simulation study. *BCM Medical Research Methodology* 2014; **14**(1): 12.